A trial of fetal cells for Parkinson’s disease brings lessons for the field

1. Barker, R. A. et al. Nat. Biotechnol. https://doi.org/10.1038/s41587-025-02567-2 (2025).

   Article 
   PubMed 
   
   Google Scholar 

2. Olanow, C. W. et al. Ann. Neurol. 54, 403–414 (2003).

   Article 
   PubMed 
   
   Google Scholar 

3. Freed, C. R. et al. N. Engl. J. Med. 344, 710–719 (2001).

   Article 
   CAS 
   PubMed 
   
   Google Scholar 

4. Dorsey, E. R. & Bloem, B. R. JAMA Neurol. 75, 9–10 (2018).

   Article 
   PubMed 
   
   Google Scholar 

5. Armstrong, M. J. & Okun, M. S. JAMA 323, 548–560 (2020).

   Article 
   PubMed 
   
   Google Scholar 

6. Li, W. et al. Proc. Natl Acad. Sci. USA 113, 6544–6549 (2016).

   Article 
   CAS 
   PubMed 
   PubMed Central 
   
   Google Scholar 

7. Politis, M. et al. Sci. Transl. Med. 2, 38ra46 (2010).

   Article 
   PubMed 
   
   Google Scholar 

8. Nakamura, T. et al. Ann. Neurol. 50, 181–187 (2001).

   Article 
   CAS 
   PubMed 
   
   Google Scholar 

9. Tabar, V. et al. Nature 641, 978–983 (2025).

   Article 
   CAS 
   PubMed 
   PubMed Central 
   
   Google Scholar 

10. Sawamoto, N. et al. Nature 641, 971–977 (2025).

    Article 
    CAS 
    PubMed 
    PubMed Central 
    
    Google Scholar 

Download references

Authors and Affiliations

1. Department of Neurosurgery, Cancer Biology and Genetics and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

   Viviane Tabar

Corresponding author

Correspondence to
Viviane Tabar.

Competing interests

V. Tabar is a scientific consultant for BlueRock Therapeutics.